These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 32015013)

  • 1. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
    Casey DL; Cheung NV
    Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in immunotherapy for pediatric solid tumors.
    Schultz LM; Majzner R; Davis KL; Mackall C
    Curr Opin Pediatr; 2018 Feb; 30(1):30-39. PubMed ID: 29189429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
    Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
    Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obstacles to T cell migration in the tumor microenvironment.
    Nicolas-Boluda A; Donnadieu E
    Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
    Trujillo JA; Sweis RF; Bao R; Luke JJ
    Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cold Tumors: A Therapeutic Challenge for Immunotherapy.
    Bonaventura P; Shekarian T; Alcazer V; Valladeau-Guilemond J; Valsesia-Wittmann S; Amigorena S; Caux C; Depil S
    Front Immunol; 2019; 10():168. PubMed ID: 30800125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
    Tesfaye M; Savoldo B
    Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular targets for development of cancer immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
    Scarfò I; Maus MV
    J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Ovarian Cancer.
    Wang W; Liu JR; Zou W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.
    Egen JG; Ouyang W; Wu LC
    Immunity; 2020 Jan; 52(1):36-54. PubMed ID: 31940272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
    Wu J; Cai J
    Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.